TMCI vs ZBH
TMCI: Treace is a focused orthopedic medical device company specializing in innovative 3D bunion correction and foot surgery systems for hospitals and surgical centers. ZBH: A global leader in musculoskeletal healthcare, providing a comprehensive portfolio of reconstructive implants, sports medicine, and trauma technologies to restore patient mobility.
Side-by-side fundamentals
| Metric | TMCI | ZBH | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.97 | $88.68 | |
| Market cap as of 2026-07-23 | $258M | $17.5B | |
| P/E as of 2026-07-23 | n/a | 22.96 | |
| PEG as of 2026-07-23 | -0.35 | 4.19 | TMCI lower |
| Net margin as of 2026-07-23 | -29.4% | +9.1% | ZBH higher |
| Gross margin as of 2026-07-23 | +79.7% | +70.0% | TMCI higher |
| Operating margin as of 2026-07-23 | -28.2% | +14.0% | ZBH higher |
| ROE as of 2026-07-23 | -69.5% | +6.0% | ZBH higher |
| ROA as of 2026-07-23 | -31.4% | +3.3% | ZBH higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.59 | ZBH lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.7% | +9.2% | ZBH higher |
| Revenue CAGR (3y) SEC XBRL | +14.5% | +5.9% | TMCI higher |
| Dividend yield as of 2026-07-23 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.40 | 0.47 | |
| 1-year return as of 2026-07-22 close | -26.0% | -8.1% | ZBH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.